Kidney Week

Abstract: SA-PO1253

Data from a Novel Prospective Onconephrology Clinic Registry: Comparison of Initial Data from Two Tertiary Care Centers

Session Information

• Onconephrology: Epidemiological Trends, Risk Stratification, and Clinical Outcomes
  October 24, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Onconephrology

• 1600 Onconephrology

Authors

• Gork, Ittamar, Hadassah University Medical Center, Jerusalem, Jerusalem District, Israel

Ittamar Gork, MD

• Kitchlu, Abhijat, University Health Network, Toronto, Ontario, Canada

Abhijat Kitchlu, MD, MS, MSc

Background

Onconephrology clinics are increasingly established worldwide, however prospective clinic registries have not been reported. We describe clinical data from the first year of a novel onconephrology clinic registry in Hadassah Medical Center (HMC). We compare characteristics with data from the University Health Network (UHN) in Toronto, Canada.

Methods

Prospectively collected pre-specified patient data (demographic and clinical data) from April 2025 to May 2026 were included. Comparisons were made with similar data, prospectively collected from June 2019 to May 2021 in the UHN registry.

Results

The HMC and UHN registries included 152 and 411 patients, respectively. Median eGFR was lower at HMC (54 vs. 62 ml/min/1.73m², p-value <0.001). The HMC registry’s most frequent cancer sites were plasma cell dyscrasias and other hematologic malignancies (12.5 and 13.2% respectively). Breast cancer was also common at 12.5%. While similar prevalence was seen of most malignancies, breast cancer was more prevalent in the HMC registry and genitourinary malignancies were more common in the UHN registry (Figure 1). CKD stages 4-5 were more prevalent in the HMC registry (p-value <0.001). Specific comorbidities were more frequent in the HMC cohort: heart failure (11 vs 4.9%, p = 0.013); cardiovascular disease (24 vs 11%, p < 0.001) and smoking (23 vs 7.1%, p <0.001).

Conclusion

This is the first report of patient characteristics from two onconephrology clinic registries. Our data suggests that establishing onconephrology clinic registries may allow greater understanding of this patient population. We also demonstrate that clinic registries can be compared, especially when designed similarly. Our hope is that this may allow us to better understand outcomes of onconephrology patients and of kidney complications during specific cancer therapies across various centers.

Figure 1: Distribution of main cancer cites by cohort. HAD, Hadassah medical center; UHN, University health network